Due to the unique immune substrates of NPC, including abundant lymphocyte infiltration, high expression of PD-1, and the presence of multiple immune targets (CD40, CD70, CD80, and CD86), the inclusion of ICIs, for example PD-1 inhibitors in the treatment of NPC has a strong biological basis (25). The gene discussed is CD80; the disease is nasopharyngeal carcinoma.